These assignments were based on areas of particular expertise of writing committee members. All recommendations were fully reviewed and discussed among the full committee to allow for diverse perspectives and considerations for this guideline. Recommendations were then voted upon, with a modified Delphi process used to reach consensus. 1.2. Organization of the Writing Committee The writing committee consisted of clinicians, cardi- ologists, health services researchers, epidemiologists, internists, nurses, and a lay representative. The writing committee included representatives from the ACC and AHA. Appendix 2 of the present document lists writing committee members relevant RWI. For the purposes of full transparency, the writing committee members com- prehensive disclosure information is available online. 1.3. Document Review and Approval This document was reviewed by 5 official reviewers nominated by the ACC and AHA (1 reviewer from the ACC/AHA Task Force for Practice Guidelines, 2 review- ers from the AHA, and 2 reviewers from the ACC); 3 reviewers on behalf of the American Association of Car- diovascular and Pulmonary Rehabilitation, the American Society for Nutrition, and the American Society of Pre- ventive Medicine; and 23 individual content reviewers. Reviewers RWI information was distributed to the writ- ing committee and is published in this document (Ap- pendix 3). This document was approved for publication by the governing bodies of the ACC and AHA. 1.4. Scope of the Guideline This guideline is intended to be a resource for the clini- cal and public health practice communities. It addresses the primary prevention of CVD in adults ( 18 years of age), focused on outcomes of ASCVD (ie, acute coronary CLINICAL STATEMENTS AND GUIDELINES syndromes, MI, stable or unstable angina, arterial re- vascularization, stroke, transient ischemic attack, or peripheral arterial disease of atherosclerotic origin), as well as heart failure and atrial fibrillation. 